V1RC18 Inhibitors
V1RC18 inhibitors constitute a class of chemical compounds that are defined by their molecular action, specifically targeting a particular biological pathway. These inhibitors are designed to interact with a very specific site within a biological system, the V1RC18 receptor. This receptor is part of a larger family of receptors that play critical roles in the cellular signaling processes. The V1RC18 receptor, like others in its family, consists of protein structures that traverse the cell membrane and are involved in the transmission of signals from outside the cell to the inside, which in turn can affect various cellular functions. The inhibitors work by binding to the receptor at its active site, which is the part of the receptor that interacts with its natural ligands – the molecules that normally bind to the receptor to activate or deactivate its signaling function.
The molecular structure of V1RC18 inhibitors is characterized by a complexity that allows them to fit precisely into the receptor's active site, much like a key fits into a lock. This specificity is achieved through a process of rational drug design, where the molecular structure of the target receptor is analyzed and inhibitors are crafted to achieve an optimal fit. The interaction between a V1RC18 inhibitor and the receptor is typically governed by a variety of intermolecular forces such as hydrogen bonds, hydrophobic interactions, and van der Waals forces. This precise interaction effectively blocks the natural ligands from binding to the receptor and can modulate the receptor's signaling ability. The design of these inhibitors is a meticulous process that often requires the iterative synthesis and testing of numerous compounds to identify those with the most potent and selective receptor-blocking characteristics. The chemical synthesis of V1RC18 inhibitors involves a series of reactions that must be carefully conducted to ensure the final product possesses the desired specificity and high affinity for the V1RC18 receptor.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This macrolide compound inhibits mTOR (mechanistic target of rapamycin), which is a crucial kinase that V1RC18 may signal through for cellular growth and proliferation. Inhibition of mTOR leads to a reduction in the activity of downstream effectors that V1RC18 may utilize, thus decreasing V1RC18's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of the PI3K (phosphoinositide 3-kinases), LY294002 prevents the phosphorylation and activation of AKT, a downstream target that could be critical for V1RC18 signaling involved in cell survival and growth. By blocking this pathway, LY294002 indirectly lowers V1RC18's functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 impairs the pathway's ability to transmit signals that may be essential for V1RC18's role in cell division and differentiation, thus indirectly inhibiting the functional activity of V1RC18. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Since p38 MAPK is involved in inflammatory responses and stress, its inhibition could diminish the functional signaling that V1RC18 may be involved in, particularly if V1RC18 has a role in cellular responses to stress or cytokine signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a highly selective inhibitor of both MEK1 and MEK2, components of the MAPK/ERK pathway. This inhibition can reduce the activity of ERK, which may be a downstream component of V1RC18's signaling cascade, thereby decreasing V1RC18's functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK (c-Jun N-terminal kinases), SP600125 disrupts the JNK signaling pathway, which is involved in apoptosis, cell differentiation, and proliferation. If V1RC18 relies on JNK signaling, SP600125's action would result in reduced functional activity of V1RC18. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
IWP-2 inhibits Wnt production by blocking porcupine, an O-acyltransferase required for Wnt secretion and activity. If V1RC18 is part of a pathway downstream of Wnt signaling, inhibiting Wnt production would indirectly decrease V1RC18's functional activity. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
This compound is an inhibitor of BMP signaling and can block the kinase activity of AMPK. If V1RC18 is involved in pathways downstream of BMP or energy homeostasis regulated by AMPK, Dorsomorphin would lead to diminished functional activity of V1RC18. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 is an inhibitor of the STAT3 activation pathway. STAT3 is involved in various cellular processes including growth and differentiation. If V1RC18's function is linked to STAT3-mediated signaling, inhibition by S3I-201 would decrease V1RC18's activity. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
A specific inhibitor of p70S6 kinase, PF-4708671 disrupts the downstream signaling of the mTOR pathway. Since p70S6 kinase is important for protein synthesis and cell growth, inhibition by PF-4708671 could indirectly lower V1RC18's functional activity if it is linked to mTOR signaling. | ||||||